Authenticating medicines with dual laser handheld Raman spectroscopy by Assi, Sulaf
Handheld Raman spectroscopy offers this advantage since these
spectrometers are light in weight, have long battery lifetimes and can
operate over a wide temperature range, including both hot and cold
climates2,3. However, one issue that is often encountered with
authenticating medicines using handheld Raman spectroscopy, and
mainly attributed to the Raman activity of authenticated medicines, 
is that drugs with low API contents and high excipient concentrations
often fluoresce and have weak Raman activity3,4. The latter phenomenon
is often encountered when using a 785nm laser, which is used since it
has the advantage of high sensitivity. Fluorescence can be mitigated by
using a further wavelength laser (such as a 1064nm one); however, this
risks lower sensitivity5. 
The use of dual laser handheld Raman spectroscopy was successful
in the chemical characterisation and authentication of type 5
The World Health Organisation (WHO) defines counterfeit medicines as those that have been “deliberately and
fraudulently mislabelled according to identity or source’”1. Such illegitimate drugs can have defects in their active
pharmaceutical ingredients (APIs), excipients or coating, or their packaging might have been tampered with. 
The harm resulting from them is unpredictable and can range from treatment ineffectiveness to drug resistance and
even death. Additionally, drug counterfeiting is not limited to a class or formulation type and can be encountered
anywhere in the wholesale supply chain. In this respect, rapid and mobile techniques that can authenticate
medicines where they are encountered are favourable.
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phosphodiesterase inhibitors, which contained
concentrations of APIs in the range of 5-15%
m/m6. This article describes the results that
were obtained when handheld Raman was used
to authenticate medicines with low API
contents and of diverse classes. 
Experimental design
The medicines investigated in this study
included both lifesaving and lifestyle products;
these five products were the antihistamine
drug loratadine; antidepressant citalopram; 
the antihyperlipidemics atorvastatin and
simvastatin; and vardenafil, a sexual stimulant
(Table 1). All of these medicines had low doses
of APIs, in the range of 5-15% m/m. Branded
and generic batches of them were obtained
from France, India, Lebanon, Turkey, the UK and
via the Internet. Additionally, APIs and the main
excipients commonly present in the drugs were
purchased from Chemical Suppliers.
Raman spectra of medicines were acquired
using the Bruker BRAVO handheld Raman
instrument, equipped with dual laser and
charged coupled device detector with thermo -
electric cooling. Four spectra were collected from both sides of 
tablets such that tablets were rotated between measurements. 
Each spectrum was the sum of one scan over the wavenumber range of
300-3200cm-1. Spectra of APIs and excipients were collected through
transparent glass vials and each vial was shaken and repositioned after
each measurement.
Next, the spectra of APIs, excipients and medicines were exported
in Matlab 2014b where multivariate classification algorithms were
applied. The two algorithms were: correlation in wavenumber space
(CWS) and principal component analysis (PCA). For the CWS algorithm,
the test medicine spectrum was compared
against the spectra of each of the excipients
and the authentic medicine. In this sense, a
correlation coefficient value (r-value) of ≥ 0.95
indicated a match and vice versa. 
For PCA, the first two scores plots of the
authentic and counterfeit product were compared in relation to the
95% equal frequency ellipses. The 95% equal frequency ellipses were
calculated using the authentic scores. In this respect, if an authentic
score was encountered outside the ellipse, this was considered a type I
error. However, if a counterfeit score was encountered inside the
ellipse, this was considered a type II error. 
Results and discussion
Raman activity of medicines with low APIs
Both branded and generic versions of each of the five medicines in the
study were evaluated. All these medicines had API concentrations below
15% m/m and this introduced a challenge in the authentication
process. Unlike branded medicines, the excipients in generic medicines
were not always known7. Moreover, the Raman
activity of the individual medicines depends on
the activity of the API as well as the excipients. 
In general, APIs are Raman-active provided
they are present in a high concentration within
the product3. Nonetheless, the Raman activity
of excipients is often masked by fluorescence3 that impacts the Raman
activity of the overall medicine. One way of overcoming the
fluorescence of excipients is to use sequential shifted excitation (SSE)8.
In this work, SSE algorithm was used for authenticating medicines with
multiple excipients and low doses of APIs. The algorithm proved
successful in mitigating fluorescence of the medicines, yet had variable
effects on the Raman activity of the medicines where the scattering
intensity was a key factor. Though scattering intensity had arbitrary
units, its value was directly proportional to the concentration(s) of
Raman active substance(s)9. 
Hence, four parameters were taken into account when evaluating
the Raman activity of the medicines. These were: fluorescence of the
product, scattering intensity, range of scattering (over both lasers) and
noise. Where known, the number of excipients present in the medicines
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Table 1: Details of the products used in the study
Product name API Dose (mg) NTP Purchase sources
Atorvastatin atorvastatin 10 8 France, India,
calcium Lebanon,
trihydrate Turkey, UK
Citalopram citalopram 10 10 Lebanon, UK
hydrobromide
Loratadine loratadine 10 11 Internet, UK
Simvastatin simvastatin 20 Lebanon, UK
Vardenafil vardenafil 20 30 India, Lebanon,
hydrochloride Turkey, Internet, UK
Figure 1: Raw Raman spectra of branded products of (a) atorvastatin, (b) citalopram, (c) loratadine, (d) simvastatin
and (e) vardenafil, measured using the Bruker BRAVO handheld Raman spectrometer equipped with dual laser
Rapid and mobile techniques that
can authenticate medicines where they
are encountered are favourable 
14 European Pharmaceutical Review VOLUME 21 ISSUE 6 2016
ranged between four and 20 (Table 2). Hence,
the multiple constituents present in the
medicines affected the Raman activity of them.
It is noteworthy to mention that the number of
excipients did not affect the Raman activity 
of the medicines (Figure 1; page 13). Hence, all
the evaluated medicines, except for citalopram, had scattering
intensities in the range of 25,000 (observed for atorvastatin) and 60,000
arbitrary units (observed for simvastatin). 
Citalopram had a scattering intensity of 5,000 arbitrary units;
however, it showed numerous peaks over the two laser wavenumbers
(the first laser up to 2,000 cm-1 and the second between 2,000 and
3,000cm-1). The remaining four medicines
showed scattering mainly in the first laser 
range (7-12 peaks), and showed only one 
peak in the second laser range correspond-
ing to the CH group. None of the medicines
showed fluorescence within their spectra.
Moreover, all medicines’ spectra showed minimum noise (S/N ratio 
in the range of 10-40).
Spectral evaluation of medicines
In both laser ranges, the spectra of the medicines showed
corresponding peaks to the API, main excipient and titanium dioxide
where present (Figures 1 and 2). Corresponding APIs’ peaks showed
scattering in the range of 1,000-2,000cm-1 and around 3,000cm-1. 
The main excipients (being lactose and microcrystalline cellulose)
showed scattering over the full wavelength range when titanium dioxide
was not present. Thus, the presence of titanium dioxide masked the
signal between 300 and 700cm-1. In this case, the presence of titanium
dioxide was detected in all products except for loratadine, which 
was not film coated (Figure 1). This is useful since it enables the
thickness of coating to be detected by observing the scattering 
of titanium dioxide6. 
Regarding the main excipients, lactose was present in three
products: atorvastatin, loratadine and simvastatin (Table 2) 
with featured peaks around 1,000cm-1 Furthermore, micro-
crystalline cellulose was featured in the spectra of citalopram and
vardenafil (between 1,000 and 1,500cm-1) as it was their main excipient.
The featuring of the main excipient in the spectra of medicines was
useful in allowing one to compare when the generic medicine con-
tained the same main excipient as the branded medicine. This was the
case in this work, where lactose and MCC spectral features were seen in
the spectra of the generic test medicines.
Spectral authentication of medicines
Subsequently, the spectra of the test medicines were compared 
against the authentic medicines, titanium dioxide and the main
excipients’ spectra. For atorvastatin medicines tested, six products
matched the spectra of the authentic medicine (r value = > 0.98), and
showed r values in the range of 0.85-0.92 and 0.17-0.32 for lactose 
Table 2: Constituents of the products used in the study
Product API Main excipient List of excipients
Atorvastatin atorvastatin lactose calcium carbonate,
calcium monohydrate microcrystalline cellulose,
trihydrate lactose monohydrate,
croscarmellose sodium,
polysorbate 80, hydroxypropyl
cellulose, magnesium stearate,
hypromellose, macrogol 8000,
titanium dioxide, talc,
simethicone emulsion
Citalopram citalopram microcrystalline mannitol, microcrystalline
hydrobromide cellulose cellulose, colloidal anhydrous
silica, magnesium stearate,
hypromellose, titanium dioxide,
macrogol 6000
Loratadine loratadine lactose lactose monohydrate,
monohydrate microcrystalline cellulose, maize
starch, magnesium stearate
Simvastatin simvastatin lactose butylated hydroxyanisole,
monohydrate ascorbic acid, citric acid
monohydrate, microcrystalline
cellulose, pregelatinised maize
starch, lactose monohydrate,
magnesium stearate,
hypromellose, hydroxy propyl
cellulose, titanium dioxide, talc,
iron oxide yellow, iron oxide red
Vardenafil vardenafil microcrystalline crospovidone, magnesium
hydrochloride cellulose stearate, microcrystalline
cellulose, colloidal anhydrous
silica, macrogol 400,
hypromellose, titanium 
dioxide, ferric oxide yellow,
ferric oxide red
API: Active pharmaceutical ingredient
Figure 2: Raw Raman spectra of branded products of (a) lactose, (b) MCC and (c) TiO2, measured using the Bruker BRAVO handheld Raman spectrometer equipped with dual laser
handheld dual laser Raman
equipped with SSE was successful in
characteristing medicines with low
amounts of APIs 
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and titanium dioxide, respectively. One
atorvastatin test medicine failed the
identification as it mismatched the authentic
product and showed an r value of 0.78 against
the authentic reference (Figure 3). The
aforementioned test medicine showed r values
for lactose and titanium dioxide of 0.69 and
0.29, respectively. This indicated that this batch
had the main ingredients listed but in different
amounts than the authentic reference. 
Figure 4 (page 16) shows the correlation
map of test atorvastatin tablets against the
reference medicine, lactose and titanium
dioxide. A high match (ir values of 0.95-1) is
displayed in a dark red colour, whereas a high
dissimilarity (r values of around 0) is shown in
dark blue. In this respect, authentic batches
(columns and rows 13-50) showed r values of
above 0.98. On the other hand, the counterfeit
batch (columns and rows 51-60) showed 
r values in the range of 0.77-0.79 against the
authentic reference. 
Similarly, mismatches were also encount -
ered when authenticating vardenafil products.
In this respect, authentic vardenafil batches gave r values in the range
of 0.96-0.98, 0.46-0.58 and 0.70-0.92 against the reference medicine,
lactose and titanium dioxide. Conversely, counterfeit vardenafil batches
gave r values in the range of 0.78-0.92, 0.13-0.83 and 0.38-0.95 against
the reference medicine, lactose and titanium dioxide. This indicated the
diversity and inconsistency of ingredients present in the counterfeit
batches evaluated. 
On the other hand, no mismatches were observed for citalopram,
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Figure 3: Raw Raman spectra of authentic (blue) counterfeit (red) atorvastatin products measured using the Bruker
BRAVO handheld Raman spectrometer equipped with dual laser
loratadine and simvastatin medicines
evaluated. Accordingly, the ten
citalopram medicines evaluated gave 
r values of above 0.99 for the citalopram
reference medicine. Additionally, they
gave r values in the range of 0.72-0.92
and 0.3-0.41 for titanium dioxide and
microcrystalline cellulose, respectively.
The identical match between the afore -
mentioned ten batches and the
authentic reference could indicate they
were from the same manufacturing
source as the authentic product.
Likewise, loratadine and simvastatin
medicines gave r values of above 0.96
against their authentic references.
Additionally, loratadine gave r values in
the ranges of 0.93-0.95 and 0.01-0.012 for
lactose and titanium dioxide. This was because loratadine medicines
had high concentrations of lactose in their formulations and no
titanium dioxide. On the other hand, simvastatin medicines showed 
r values in the ranges of 0.48-0.63 and 0.70-0.84 for lactose and titanium
dioxide, which corresponded to the excipient content and coating. 
To confirm the reliability of the correlation method in authenticating
the aforementioned medicines, PCA was applied to the spectra of
authentic and counterfeit batches. For most medicines, PCA was able to
confirm the correlation results with no type I or type II errors. Type I
errors were only encountered when authenticating atorvastatin and
loratadine medicines (Figure 5). Two authentic atorvastatin batches 
and seven authentic loratadine batches were misclassified using the
95% equal frequency ellipse. This could be attributed to the diversity of
matrices among the medicines. Subsequently, future work should look
into a more quantitative approach for APIs and main excipients in
medicines with diverse matrices.
Conclusion
In summary, handheld dual laser Raman equipped with SSE was
successful in characteristing medicines with low amounts of APIs. 
The SSE algorithm showed to be successful in mitigating the
fluorescence encountered when multiple excipients were present in 
the formulation. Additionally, correlation and the PCA method were
successful in authenticating the majority of the products. Few products
showed type I errors when classified using PCA. Thus, future work will
involve the development of quantitative models for authenticating
branded and generic medicines.
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Figure 4: Correlation map of the Raman spectra of (1) titanium dioxide, (2) lactose, 
(3-50) authentic atorvastatin and (51-60) counterfeit atorvastatin. The colour map on
the right shows the corresponding range to the r values. A perfect match (r = 1) is
displayed in dark red, whereas a perfect mismatch (r = negative) is displayed in 
dark blue
Figure 5: PCA scores plot of the Raman spectra authentic (blue) and counterfeit (red) of (a) atorvastatin and (b) loratadine
medicines with the 95% equal frequency ellipses plotted around the authentic scores
